EC
SRPT icon

EntryPoint Capital’s Sarepta Therapeutics SRPT Stock Holding History

EntryPoint Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,409
Closed -$409K – 806
2025
Q1 		$409K Buy
+6,409
New +$675K 0.19% 182
2024
Q3 		– Sell
-1,344
Closed -$212K – 1288
2024
Q2 		$212K Buy
+1,344
New +$173K 0.1% 377

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

EntryPoint Capital's SRPT Position: Q2 2025 in Review

EntryPoint Capital sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 6,409 shares — an estimated $409K sold.

EntryPoint Capital first reported a position in SRPT in Q2 2024 and held it in 2 quarters. The position peaked at $409K in Q1 2025. 363 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • EntryPoint Capital reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • EntryPoint Capital sold 6,409 Sarepta Therapeutics shares in Q2 2025, an estimated $409K.
  • EntryPoint Capital first reported a position in Sarepta Therapeutics in Q2 2024 and held it in 2 quarters.
  • EntryPoint Capital's Sarepta Therapeutics position peaked at $409K in Q1 2025.
  • 363 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on EntryPoint Capital's 13F filing for Q2 2025, filed 11 Aug 2025.